

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Research into the Renal and Cardiovascular Effect of Sodium-Glucose co-Transporter 2 (SGLT2) inhibition in combination with Loop Diuretics in Diabetic patients with Chronic Heart Failure (RECEDE-CHF): A Randomised Controlled Double-Blind Crossover Trial: Trial Rationale and Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018097
Article Type:	Protocol
Date Submitted by the Author:	23-Jun-2017
Complete List of Authors:	Mordi, Natalie; University of Dundee Division of Cardiovascular and Diabetes Medicine Mordi, Ify; University of Dundee Division of Cardiovascular and Diabetes Medicine Singh, Jagdeep; University of Dundee Division of Cardiovascular and Diabetes Medicine Baig, Fatima; University of Dundee Division of Cardiovascular and Diabetes Medicine Choy, Anna-Maria; University of Dundee Division of Cardiovascular and Diabetes Medicine McCrimmon, Rory; University of Dundee Division of Cardiovascular and Diabetes Medicine Struthers, Allan; University of Dundee, Division of Cardiovascular and Diabetes Medicine Lang, Chim C.; University of Dundee Division of Cardiovascular and Diabetes Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Diabetes and endocrinology, Pharmacology and therapeutics, Research methods
Keywords:	Sodium-Glucose co-Transporter 2 (SGLT2) Inhibitors, Heart failure < CARDIOLOGY, Diabetes Mellitus, Natriuresis, Diuresis

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Research into the Renal and Cardiovascular Effect of Sodium-Glucose co-Transporter 2 (SGLT2) inhibition in combination with Loop Diuretics in Diabetic patients with Chronic Heart Failure (RECEDE-CHF): A Randomised Controlled Double-Blind Crossover Trial: Trial Rationale and Protocol

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Natalie A. Mordi* MRCP n.a.mordi@dundee.ac.uk, **Ify R. Mordi MD MRCP** i.mordi@dundee.ac.uk, **Jagdeep S. S. Singh MRCP** j.x.singh@dundee.ac.uk, **Fatima Baig BSc.** f.z.baig@dundee.ac.uk, **AnnaMaria Choy FRCP FACC** a.choy@dundee.ac.uk, **Rory J. McCrimmon MD** r.mccrimmon@dundee.ac.uk, **Allan D. Struthers MD FRCP** a.d.struthers@dundee.ac.uk, **Chim C. Lang MD FACC** c.c.lang@dundee.ac.uk

***Correspondence:**

Dr Natalie A. Mordi

Division of Molecular and Clinical Medicine, Mailbox 2, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK

Phone: +44-1382-383013

Email: n.a.mordi@dundee.ac.uk

Short title: SGLT2 Inhibition in combination with diuretics in heart failure

Word Count: Abstract: 285. Excluding title page, abstract, references, figures and tables: 4627

Key words: Heart failure, diabetes mellitus, sodium-glucose co-transporter 2 (SGLT2) inhibitors, natriuresis, diuresis

Version 1.5. 23rd June 2017

ABSTRACT

Objectives: To assess the effect of Sodium-Glucose Linked Co-Transporter 2 (SGLT2) inhibitors when used in combination with a loop diuretic on diuresis and natriuresis when compared to placebo. We hypothesise that in those with Type 2 Diabetes (T2D) and Chronic Heart Failure (CHF), SGLT2 inhibition may augment the effects of loop diuretics.

Setting: The RECEDE-CHF trial is a single centre, randomised double-blind, placebo-controlled, crossover trial conducted in a secondary care setting within NHS Tayside, Scotland.

Participants: 34 eligible participants, aged between 18 to 80 years, with stable T2D and well-controlled CHF will be recruited. Participants will be excluded where there is a diagnosis of chronic liver disease, renal impairment or hypotension (systolic BP < 95 mmHg) at the screening visit.

Interventions: Renal physiological testing will be performed at two points (week 1 and week 6) on each arm to assess the effect of 25mg empagliflozin, on the primary and secondary outcomes, when compared to placebo. There will be a two-week washout period between each arm. Participants will be enrolled in the trial for a total period between 14 to 16 weeks.

Outcome measures: The primary outcome is to assess the effect of empagliflozin versus placebo on urine output. The secondary outcomes for this trial are to assess the effect of empagliflozin on

- urinary sodium excretion
- glomerular filtration rate

- creatinine
- protein/creatinine ratio
- albumin/creatinine ratio
- and on the renal biomarker, cystatin C when compared to placebo.

Conclusions: In this proof of concept trial, we hypothesise that the benefits of SGLT2 inhibitors extend beyond those of their metabolic (glycaemic parameters and weight loss) and haemodynamic parameters; that the effects of SGLT2 inhibitors as an osmotic diuretic and on natriuresis may underlie the cardiovascular and renal benefits demonstrated in the recent EMPA-REG study.

Trial registration: will be in place by the commencement of the trial.

ARTICLE SUMMARY

STRENGTHS AND LIMITATIONS

- **Original proof of concept study that aims to explore the effect on diuresis and natriuresis of SGLT2 inhibitors in combination with furosemide**
- **Randomised, double-blind crossover study design**
- **Small, single centre study**
- **High participant dropout rate has been factored into power calculations**
- **Aims to shed light on the mechanism of the cardiovascular benefits seen in EMPA-REG OUTCOME trial**

BACKGROUND

Chronic heart failure (CHF) and type 2 diabetes (T2D) frequently coexist. In population-based studies and in CHF trials, the prevalence of T2D among patients with symptomatic HF is estimated to be between 12% and 41%.¹ T2D has consistently been shown to be an independent predictor of increased morbidity and mortality in patients with CHF.²

For most patients, metformin is the first choice anti-diabetic drug in all T2D patients including those with coincidental HF.³ However, metformin alone is often not enough to keep glycaemia under control and there is a frequent need for a second line anti-diabetic drug in HF patients. Sulphonylureas (SU) are commonly prescribed in T2D however they are associated with weight gain and hypoglycaemia, while there remain concerns that SUs may increase all-cause and cardiovascular (CV) mortality,⁴ although this link is not fully established. Glitazones are contra-indicated in New York Heart Association (NYHA) III or IV HF, while their role in milder degrees of HF remains to a certain extent controversial with some observational studies indicating increased hospitalisation or readmission due to HF.⁵ Insulin use has also been associated with increased mortality in patients with CHF.⁶ More recent agents such as the DPP-IV inhibitors have also, disappointingly, failed to show cardiovascular benefit with some concerns raised following the publication of SAVOR-TIMI-53, that they increased HF hospitalisations, although these trials have only been of short duration⁷ and may not apply to all DPP-IV inhibitors. Therefore, it can be concluded that therapeutic options in DM and HF limited due to a lack of evidence-based guidelines on the optimal management of such patients. Indeed, international guidelines recognize the evidence gap on the safety and efficacy of drugs used to treat DM in patients with HF as well as the need for agents that will both improve overall glycaemic control and HF outcomes.⁸

SGLT2 Inhibitors and HF

SGLT2 inhibitors are licensed for use in patients with T2D. These oral anti-diabetic agents achieve their effects by blocking the low affinity, high capacity Type 2 Sodium-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Glucose Linked Co-Transporter (SGLT2), predominantly found in the proximal convoluted tubules of the kidneys, thus causing glycosuria. The recent landmark EMPA-REG outcome study reported a striking 35% relative risk reduction in HF hospitalisations with empagliflozin may provide supportive evidence for beneficial effects of SGLT2 inhibition in the setting of CHF.⁹ A recent analysis of the EMPA-REG study showed that empagliflozin reduced HF hospitalization and cardiovascular death, with a consistent benefit in patients with and without baseline HF.¹⁰

The effect of empagliflozin on HF hospitalization or CV death and on all-cause hospitalization was observed very early and was sustained throughout the trial. This suggests that the benefit was not driven by an effect on atherosclerosis. The mechanisms behind the effects of empagliflozin on HF and CV death are unknown. It has been hypothesised that the benefits of SGLT2 inhibitors extend beyond those of the glycaemic parameters of weight loss as promoted by glycosuria, but the effects of SGLT2 inhibitors on non-glycaemia parameters including blood pressure lowering as well as osmotic diuretic and natriuretic effects which may underlie the cardiovascular (and renal) benefits.^{11,12}

Renal effects of SGLT2 inhibition and co-prescribing with Loop Diuretics

The renal effects of SGLT2 inhibitors are attracting much recent interest as they may confer renal protection.^{13,14} There is data to support the potential for direct renoprotective actions arising from SGLT2 inhibition including actions to attenuate T1D associated hyperfiltration through an effect on tubulo-glomerular (TG) feedback which may have renal-protective effects by decreasing glomerular hydrostatic pressure.^{13,14} SGLT2 inhibition has also been shown to attenuate tubular hypertrophy and reduce the tubular toxicity of glucose.¹⁵ They may also have indirect renoprotective effects through its blood pressure lowering effects and glycaemia lowering effects which could decrease the renal inflammatory and fibrotic response by blocking glucose entry into the cell.¹⁵ Consequently, there are now several on-going SGLT2 inhibitor renal outcome trials in T2D, including the CANVAS-R trial (clinicaltrials.gov identifier NCT01989754) and the CREDENCE trial (clinical trials.gov identifier NCT02065791). However, neither trial specifically looks at T2DM patients with CHF.

1
2
3 Studies relating to diuresis in the context of SGLT2 inhibitors are surprisingly sparse.¹²
4
5 Previous studies with empagliflozin and canagliflozin have demonstrated a 24 hour
6
7 urinary increase by 300 ml/day after day 1 of treatment but that the daily urinary volume
8
9 returned to baseline after several weeks.^{16,17} One Japanese case report however, in a
10
11 non-diabetic patient, described successful treatment of fluid overload that was initially
12
13 resistant to diuretic therapy, with 5 days of treatment of 50mg ipragliflozin.¹⁸

14
15 In post-hoc analysis of EMPA-REG OUTCOME, Fitchett et al. reported reduced use of
16
17 furosemide in patients on the empagliflozin arm, suggesting that these patients reached
18
19 a relative state of euvolaemia.^{10,12} Heerspink et al. highlighted that, volume depletion
20
21 and associated use of loop diuretic is long associated with a pre-renal cause of acute
22
23 kidney injury, and a decrease in loop diuretic may also be relevant in light of the
24
25 reductions in acute kidney injury, acute renal failure and chronic kidney disease
26
27 progression endpoints.^{12,19}

28
29 The renal effects of SGLT2 inhibitors in combination with furosemide in T2D with CHF
30
31 are not known but given the relative frequency of both co-morbidities they are likely to
32
33 be prescribed concurrently. This underscores the need for a trial to provide detailed
34
35 acute and long-term information regarding the renal effects of SGLT2 inhibition in
36
37 combination with loop diuretics, in T2D patients with stable CHF.

38
39 We hypothesize that SGLT2 inhibitors may be able to address the issue of diuretic
40
41 resistance and may augment the diuretic effects of furosemide in patients with T2D and
42
43 CHF.

44
45 We will recruit diabetic HF patients taking stable doses of furosemide, or, alternative
46
47 loop diuretics, with eGFR greater than 45ml/min/1.73m². This trial will, with careful
48
49 monitoring, begin the process of uncovering the unrealised potential of this new class of
50
51 drug which, for the reasons outlined above, is poised to become the 2nd line anti-
52
53 diabetic agent of choice in HF patients.


54 55 **METHODS**

56 57 **Trial design**

58
59
60

The RECEDE-CHF Trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover, trial conducted in NHS Tayside, Scotland to compare the SGLT2 inhibitor empagliflozin 25mg, to placebo. Participants will be enrolled in the trial for a period of between 14 to 16 weeks. The trial design is summarised in **Figure 1 and Table 1.**

Figure 1: RECEDE-CHF Trial Design



*BIOSTAT: Tayside database of the systems biology study to tailored treatment in chronic heart failure

**SHARE: The Scottish Health Research Register

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. RECEDE-CHF Trial Protocol

Visit	Visit 1* Screening	Visit 2* Baseline/ Randomisation	Visit 3	Visit 4 (Tele Visit)	Visit 5	Two week wash- out period	Visit 6	Visit 7	Visit 8 (Tele Visit)	Visit 9 (Final Visit)****
Week	Up to 4 weeks pre visit 2	Day 0	Day 3 (+/-2 days)	Week 3 (+/- 3 days)	Week 6 (+/- 3 days)		Week 9 (+/- 3 days)	Week 9 + 3 days (+/- 2 days)	Week 12 (+/- 3 days)	Week 15 (+/- 3 days)
Informed Consent	X									
Inclusion/Exclusion Criteria	X	X					X	X		
Past Medical History	X									
Demographics	X				X		X			X
Vital Signs	X	X	X		X		X	X		X
Safety Bloods	X	X	X		X		X	X		X
Research Bloods		X	X		X		X	X		X
Genetic Blood Sample**		X								
uPCR/uACR		X	X		X		X	X		X
Urine Pregnancy Test***	X	X	X		X		X	X		X
24 urinary collection			X		X			X		X
Renal Physiology Test			X		X			X		X
Drug Dispensing		X					X			
AE assessment		X	X	X	X		X	X	X	X
Record/Review Meds	X	X	X	X	X		X	X	X	X
Drug Compliance			X	X	X			X	X	X

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Check										
-------	--	--	--	--	--	--	--	--	--	--

Visits 1 and Visits 2 combined into one visit where able *

Genetic Blood Sample** - only to be taken if participant consent given.

Urine Pregnancy Test*** - testing on females of childbearing potential or who do not abstain from sex or use effective contraception.

Final Visit**** - if the participant wishes to withdraw prematurely or at the PI's discretion, all study procedures will be conducted as though the final visit, if participant agrees.

uPCR/uACR urine protein/creatinine ratio, urine albumin/creatinine ratio

peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

At the screening visit, following informed consent, an initial medical history and clinical examination will be performed and concomitant medication will be recorded. Participants will have bloods taken for safety analysis and vital signs will be checked to confirm eligibility prior to enrolment. An assessment of suitability of the trial for the potential participant will be undertaken by the principal investigator (PI) or medically qualified delegate.

Should the participant meet the inclusion criteria and have no exclusion criteria identified, they will return for the baseline/randomisation visit at the Clinical Research Centre (CRC), Ninewells Hospital, Dundee, within four weeks post screening visit. Where able the screening visit and randomisation visits will be combined.

At the randomisation visit participants will undergo safety blood tests, vital signs and study medication will be dispensed (either empagliflozin 25mg or placebo).

Participants will continue on study medication, empagliflozin 25mg or placebo, once daily, for a period of 6 weeks. Participants will be educated on the symptoms of hypoglycaemia and given a written action plan on how to manage it in the unlikely event that it occurs.

Participants will return to the CRC 3-days (± 2 days) post-randomisation, for a study day where they will have safety and research bloods drawn, vital signs recorded and will undergo renal physiological tests (RPT). Further details of these RPT are described below.

Participants will then return again at week 6 for a study day where they will undergo RPT again, safety and research bloods will be drawn and vital signs recorded. Participants will terminate study drug, either empagliflozin 25mg or placebo, at this visit and will return to the CRC at the end of the two week wash out period (week 9).

At week 9, participants will have safety and research bloods drawn, vital signs recorded, new study medication dispensed. The RPT will then be repeated at the same intervals, at week 9 + 3 days (± 2 days) and at week 14 for the final study day. Participants will then terminate study drug, either empagliflozin 25mg or placebo.

Study population

34 patients with underlying diabetes and well-controlled chronic heart failure (CHF) will be recruited from a range of sources. The local Tayside database of the systems biology study to tailored treatment in chronic heart failure (BIOSTAT) database consisting of around 1800 patients with HF who have previously consented to be approached for future research. The investigators may also recruit from NHS Tayside diabetes and/or heart failure clinics, SHARE The Scottish Health Research Register, where participants have pre-consented to be invited for research. It is anticipated it will take up to 18 months to recruit the 34 patients for randomisation with approximately 80-100 being consented into the screening trial. We anticipate a screen failure rate of 20% and a drop-out rate of 35% after recruitment based on previous heart failure studies within this research group and the high intensity of the Renal Physiology Test days which will occur on 4 occasions in total.

Eligibility

Patients will be eligible if they:

- Aged 18 to 80 years with previously diagnosed Type 2 Diabetes Mellitus.
- Are diagnosed with NYHA Functional class II-III HF with prior echocardiographic evidence of LVSD.
- On stable doses of furosemide, or alternative loop diuretic for one month
- Stable Type 2 Diabetes (HbA1c, in the last 3 months, of 10.0% \geq and \geq 6.5%)
- Point of Care BNP > 100 pg/ml
- eGFR \geq 45 ml/min/1.73m²
- Have stable HF symptoms for at least three months prior to consent
- On stable HF therapy for at least three months prior to consent
- Have not been hospitalised for HF for at least three months prior to consent

Patients will be excluded if they:

- A diagnosis of chronic liver disease and/or liver enzymes that are twice the upper limit of normal
- Systolic BP of <95mmHg at screening visit.

- eGFR < 45 ml/min/1.73m²
- Patients on thiazide diuretics
- Malignancy (receiving active treatment) or other life threatening disease.
- Pregnant or lactating women
- Patients with difficulty in micturition e.g. severe prostate enlargement
- Patients who have participated in any other clinical trial of an investigational medicinal product within 30days
- Patients who are unable to give informed consent
- Any other reason considered by the physician to be inappropriate for inclusion.

Randomisation and treatment allocation

After successful screening for eligibility and safety, participants will be randomised to either empagliflozin 25mg/placebo or placebo/empagliflozin 25 mg in a double blind fashion in this crossover study.

The double blind medication (empagliflozin or placebo) will be prepared, packaged and labelled by our onsite clinical trials pharmaceutical manufacturer. Randomisation will be carried out by our dedicated clinical trials pharmacy using block randomisation. They will use a validated randomisation program and will securely backup both the randomisation seed and the randomisation allocation and have it available in the onsite 24-h emergency unblinding facility.

Participants will be given blinded medication. At the randomisation visit they will be dosed with either empagliflozin 25mg (6 weeks) or matched placebo (6 weeks) to continue once daily, with a 2-week washout period between each arm. Participants and their bloods (including urea & electrolytes, liver function tests, and full blood count) will be monitored as per trial schedule and medication stopped if concerns arise. If the trial drug needs to be stopped due to intolerance or adverse events, they will remain in the trial in order to do an "intention to treat" analysis.

Trial outcomes

1
2
3 The primary aim/objectives will be to assess whether empagliflozin (SGLT2 Inhibitor)
4 can augment the diuretic effects of loop diuretics in diabetic patients with mild CHF with
5 left ventricular systolic dysfunction (LVSD), as measured by urinary volume, compared
6 to placebo.
7
8
9

10
11 The secondary aims/objectives are to assess the effect of empagliflozin (SGLT2
12 inhibitor) on natriuresis when used with loop diuretics in diabetic patients with mild CHF
13 with LVSD as measured by urinary sodium excretion, to measure the safety of add-on
14 SGLT2 inhibitor therapy versus placebo on top of loop diuretics as measured by serum
15 creatinine and eGFR, to assess effects of empagliflozin on protein/creatinine ratio,
16 albumin/creatinine ratio and on the renal biomarker, cystatin C.²⁰
17
18
19
20
21
22

23 **Renal Physiology Tests**

24
25
26 Patients will attend the Clinical Research Centre (CRC), Ninewells, Dundee on 4
27 separate study days (2 while in each arm of the trial). On each study day, patients will
28 present themselves to our CRC, following an overnight fast. Two days before presenting
29 to the CRC, patients will be required to follow a 2gram sodium and 2L fluid/day
30 controlled diet. A 24-hour urinary collection will be requested the day prior to
31 presentation at the CRC for urinary volume and sodium. Patients will be asked to take
32 their morning usual medications except their investigational medicinal product
33 (empagliflozin or placebo) and furosemide (or equivalent loop diuretic).
34
35
36
37
38
39

40
41 An intravenous (IV) cannula will be placed in each arm for subsequent infusion and
42 blood sampling. Bloods will be drawn for measurement of plasma NT-proBNP and
43 cystatin C using standard protocols. A 15 ml/kg oral water load will be administered over
44 a 15 min period. Thereafter, at 30 min intervals, patients will be requested to void urine
45 until the end of the study period. The volume of urine passed will be measured and an
46 aliquot stored for later analysis. On each occasion, the volume of urine passed will be
47 measured, and an equal volume of water given to drink. In this way, a steady state
48 diuresis will be established over approximately over 3 hours, avoiding the need for
49 catheterisation. The last 30 min urinary collection during this stabilization period will be
50 taken as baseline. At + 150 minutes, each patient will receive an oral tablet of either
51
52
53
54
55
56
57
58
59
60

1
2
3 empagliflozin 25mg or placebo. At + 210 minutes, patients will be given a bolus of IV
4 furosemide at half their total daily dose.
5
6

7 Heart rate and blood pressure will be displayed continuously on an ECG oscilloscope
8 and the blood pressure measured every 60 min. Venous blood will be obtained at the
9 midpoint of each clearance period for measurement of serum sodium, osmolality and
10 creatinine. **Figure 2** outlines the protocol for the RPT test day.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Figure 2: Protocol for Renal Physiology Test Days

e.g. Time	Interval	Urine		Blood	
0730	- 30				Arrives fasted. 2 x cannula sited
0745	- 15				15mls/kg oral water load over 15 minutes
0800	0				
0830	+ 30	Void urine. Water intake equal to urine volume.			
0900	+ 60	Void urine. Water intake equal to urine volume			
0930	+ 90	Void urine. Water intake equal to urine volume.			
0945	+ 105			Bloods (serum B1) for U&Es & osmolality	
1000	+ 120	Void urine. Water intake equal to urine volume. Collect urine (urine B1) for volume, sodium, creatinine & osmolality.	B1 (90-120 mins)		
1015	+ 135			Bloods (serum B2) for U&Es & osmolality	
1030	+ 150	Void urine. Water intake equal to urine volume. Collect urine (urine B2) for volume, sodium, creatinine & osmolality	B2 (120-150 mins)		IMP administered: Oral tablet (empagliflozin 20mg or placebo)
1045	+ 165			Bloods (serum D1) for U&Es & osmolality	
1100	+ 180	Void urine. Water intake equal to urine volume.	D1 (150-180 mins)		

		Collect urine for volume, sodium, creatinine & osmolality			
1115	+ 195		D2 (180-210 mins)	Bloods (serum D2) for U&Es & osmolality	
1130	+ 210	Void urine. Water intake equal to urine volume. Collect urine for volume, sodium, creatinine & osmolality		IV Frusemide administered: half participant's screening dose	
1145	+ 225		F1 (210 – 240 mins)	Bloods (serum F1) for U&Es & osmolality	
1200	+ 240	Void urine. Water intake equal to urine volume. Collect urine for volume, sodium, creatinine & osmolality			
1215	+ 255		F2 (240-270 mins)	Bloods (serum F2) for U&Es & osmolality	
1230	+ 270	Collect urine for volume, sodium, creatinine & osmolality.		END OF STUDY PERIOD	

1
2
3 IV furosemide will be administered to eliminate variable furosemide gut absorption and
4 for practical reasons to complete the study within the set time frame due to the reduced
5 time for the peak onset of diuretic effect with IV administration.
6
7

8
9 Data on the effect of SGLT2 inhibitors and the participant's usual oral diuretic regime
10 will be gained by the collection of 24 urinary samples on the days before the RPT.²¹
11
12

13 **Tolerability**

14
15 We will monitor for tolerability of the study medication. One of the inevitable side effects
16 of empagliflozin and other SGLT2 inhibitors with the promotion of glycosuria is urinary
17 tract infections. This typically presents itself as genital mycotic infection, typically
18 *Candida albicans*, which is usually straightforward to treat. However, if patients were to
19 present with infection unresponsive to standard treatment then the trial drug would be
20 discontinued. They will also be warned of the side effects including hypoglycaemia with
21 a written action plan on how to recognise and treat in the unlikely event of a
22 hypoglycaemic episode
23
24
25
26
27
28
29

30 **Sample size and power calculations**

31
32 Power calculations were performed by the University of Dundee's Senior Medical
33 Statistician and are based on our previous data in patients with CHF²¹ as well as more
34 contemporary data.²² The sample size is based on the mean furosemide-induced
35 urinary volume and sodium excretion of 920 mls/hr (SD=250) and 300 μ mol/min
36 (SD=60) respectively. A 20% increase is expected in these parameters following SGLT2
37 inhibition. This increase in urinary volume is based on published percentage increases
38 in urinary volume in T2D patients that range from 11%-33% depending on the dose of
39 the SGLT2 inhibitor as shown by List and colleagues²³ in the available data with
40 dapagliflozin (dapagliflozin 2.5 mg: 11% increase in 24-hr urine volume; dapagliflozin 5
41 mg: 22% 11% increase in 24-hr urine volume; dapagliflozin 10 mg: 24% 11% increase
42 in 24-hr urine volume; dapagliflozin 20 mg: 27% 11% increase in 24-hr urine volume
43 and dapagliflozin 50 mg: 33% 11% increase in 24-hr urine volume). There is no data of
44 SGLT inhibition together with loop diuretics. As described previously the Japanese case
45 report of a diuretic resistant HF patient in whom fluid overload was successfully treated
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with the SGLT2 inhibitor, ipragliflozin, where a striking 50% increase in urinary volume
4 (following treatment with 50 mg daily of oral ipragliflozin for 5 days) was described.¹⁸
5
6 Based on the above, it was determined that a 20% increase in furosemide induced
7
8 increase in urinary volume and sodium excretion will be reasonable.
9

10
11 With an alpha 0.05 and power of 90%, 22 participants per arm are required, assuming
12
13 35% drop out. Since this trial is using an AB/BA crossover design, a total of 34
14
15 participants will be required, as each participant will be exposed to both arms of the trial.
16
17 The rationale for the high dropout rate, is due to the high intensity renal physiological
18
19 tests that will occur on 4 occasions for the participants, from 0730 hrs to 1400 hrs we
20
21 feel that anything less than a 35% drop out rate would be conservative.
22

23 **Data Collection**

24
25 The data will be collected by the PI or delegate on a paper case report form (CRF) with
26
27 subsequent transcription to an electronic CRF. Electronic storage will be in an
28
29 encrypted form on a password protected device. The medical notes will act as source
30
31 data for past medical history and blood results. Any data relating to general medical
32
33 history will be documented in the notes.
34

35 **DISCUSSION**

36
37 SGLT2 inhibition is an innovative strategy for the management of T2D, where
38
39 historically, anti-hyperglycemic interventions have focused on restoring B-cell activity,
40
41 insulin sensitivity, or tissue glucose uptake to normalise plasma glucose levels.¹²
42

43
44 In this proof of concept trial, we hypothesise that the benefits of SGLT2 inhibitors extend
45
46 beyond those of their metabolic (glycaemic parameters and weight loss) and
47
48 haemodynamic parameters; that the effects of SGLT2 inhibitors as an osmotic diuretic
49
50 and on natriuresis may underlie the cardiovascular and renal benefits.

51
52 Whilst the encouraging renal and cardiovascular outcomes demonstrated in EMPA-
53
54 REG might be explained by the modest but cumulative effect of blood pressure lowering
55
56 (mean reduction in systolic BP ~ 3 mmHg), HbA1c reduction (0.3%), and weight
57
58 reduction (~ 1kg), it is difficult to ignore the possibility that an additional mechanism may
59
60

1
2
3 also be at work.^{19,24} For example, Mudaliar et al hypothesise that empagliflozin may also
4 improve renal fuel energetics and efficiency, providing more energy efficient oxygen
5 consumption and thereby potentially less hypoxic stress on the diabetic heart and
6 kidney.²⁴
7
8
9

10
11 The SGLT2 inhibitors may also have indirect renoprotective effects through its blood
12 pressure lowering effects and glycaemia lowering effects which could decrease the
13 renal inflammatory and fibrotic response by blocking glucose entry into the cell.¹⁵
14 Consequently, there are now several on-going SGLT2 inhibitor renal outcome trials in
15 T2D, including the CANVAS-R trial (clinicaltrials.gov identifier NCT01989754) and the
16 CREDENCE trial (clinical trials.gov identifier NCT02065791). However, neither trial
17 specifically looks at T2D patients with CHF.
18
19
20
21
22
23

24 We have also described that SGLT2 inhibitors may augment the effect of loop diuretics.
25 It is noteworthy that osmotic diuretics such as mannitol have been used alone or in
26 combination with loop diuretics such as furosemide to promote diuresis in patients
27 undergoing intra-cranial surgery²⁵ and in the postoperative period to prevent acute
28 kidney injury.²⁶ In CHF, mannitol was reported to promote effective diuresis in a single
29 centre study in the US.²⁷ Importantly, in all these settings, mannitol, which is a potent
30 osmotic diuretic when used in combination with furosemide, was shown to be safe and
31 did not result in renal failure or electrolyte disturbances.
32
33
34
35
36
37
38

39 By detailing urinary volumes and sodium excretion via renal physiological tests at two
40 points 3 days and 6 weeks into the investigational medicinal product, the trial's primary
41 aims to assess the change to these markers representative of diuresis in patients on
42 empagliflozin and when compared to placebo. The effects on natriuresis, proteinuria,
43 albuminuria, cystatin C will also be studied as will the safety of add-on SGLT2 inhibition
44 versus placebo.
45
46
47
48
49

50 **LIMITATIONS**

51

52
53 Whilst power calculations have been conducted to calculate the sample size, an
54 obvious limitation is that this is a small single centre trial. The proposed trial will require
55
56
57
58
59
60

1
2
3 participants on four occasions to undergo detailed renal physiological tests, (from 0730-
4 1400) as such a dropout rate has been factored in of 35%.

5
6 Heart failure is a dynamic disease; its natural history is one of flux as the patient's
7 intravascular volume changes, their loop diuretic requirement may also fluctuate.
8
9 However, as stipulated on the inclusion criteria, we will be taking patients with heart
10 failure (BNP > 100 pg/ml) with evidence of previous LVSD, but with stable symptoms
11 and medications for 3 months, who have not had a hospital admission for heart failure
12 within this same time frame.
13
14
15
16

17 18 19 **CONCLUSION**

20
21 Whilst the osmotic diuretic hypothesis¹¹ is frequently discussed in relation to the renal
22 and cardiovascular outcomes with SGLT2 inhibition, literature on the effect of SGLT2
23 inhibitors on diuresis is currently limited. At time of writing, no studies have been
24 performed to assess the effect of loop diuretics when used in combination with SGLT2
25 inhibitors. This proof of concept trial will aim to shed light on the mechanism of the
26 cardiovascular and renal outcomes demonstrated in the recent EMPA-REG study by
27 documenting the influence of the SGLT2 inhibitors when used in combination with a
28 loop diuretic on urinary volumes and natriuresis when compared to placebo.
29
30
31
32
33
34
35

36
37 Further intent of this proposed study is to obtain data that might be relevant to the
38 design of future studies in which SGLT2 inhibitors may be considered as an adjunctive
39 agent to loop diuretics in patients who experience diuretic resistance. Although data is
40 currently limited, since HF and T2D are frequent co-morbidities, it is probable that
41 physicians may find patients requiring both SGLT2 inhibitor therapy and furosemide
42 concurrently. Only by studying this, can these fundamental issues be addressed and,
43 perhaps, inspire a change in practise.
44
45
46
47
48

49 **List of abbreviations**

50
51 T2D: type 2 diabetes, HF: heart failure, CHF: chronic heart failure, EASD: European
52 Association for the Study of Diabetes, ADA: American Diabetes Association, SU:
53 sulphonylureas, CV: cardiovascular, NYHA: New York Heart Association, DPP4V
54 inhibitors: Dipeptidyl peptidase-4, SGLT2 inhibitors: Sodium-Glucose Linked co-
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Transporter 2 inhibitors, LVSD: left ventricular systolic dysfunction, LV: left ventricular, TG: tubulo-glomerular, eGFR: estimated glomerular filtration rate, CRC: Clinical Research Centre, Ninewells Hospital, Dundee, UK, RPT: renal physiological tests, EFSD: European Foundation for the Study of Diabetes, PI: principal investigator, BIOSTAT: A systems BIOlogy Study to TAIlored Treatment in Chronic Heart Failure, SHARE: The Scottish Health Research Register, CI: Chief Investigator

DECLARATIONS

Ethics approval and consent to participate

This protocol has been reviewed by the East of Scotland Research Ethics Service. Reference number 16/ES/0137.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

ADS has received research support from Astra Zeneca, as well as lecture and consulting fees also from Astra Zeneca. CCL has received research support and consulting fees from Novartis, research support, lecture fees, and consulting fees from AstraZeneca, lecture fees from Merck Sharp & Dohme, and research support from Pfizer and Sanofi. AMC has received research support from St Jude Medical, lecture fees for Daiichi Sankyo, travel support from Boston Scientific, Biotronik, Medtronic, St Jude Medical. RJM has served on advisory boards for Novo Nordisk, Sanofi, Lilly. Rest of the authors declare no competing interests.

Funding

The RECEDE-CHF trial is funded by the British Heart Foundation (BHF grant number: 807998). NAM is a BHF funded clinical research fellow.

Authors' contributions

1
2
3 NAM participated in the design of the study, data collection and drafting the manuscript.
4
5 IM and JSS participated in the design of the study and reviewing the manuscript. FB
6
7 and AMC read and approved the final manuscript. RJM and ADS participated in study
8
9 design and coordination as well as reading and approving the final manuscript. CCL
10
11 conceived the study, participated in its design and helped draft the manuscript.
12

13 Acknowledgements

14
15 Our gratitude to all members of staff within the department of Division of Cardiovascular
16
17 and Diabetes Medicine at the University of Dundee, and the team at the Clinical
18
19 Research Centre, University of Dundee, Ninewells Hospital and Medical School, UK.
20
21
22
23

24 REFERENCES

- 25
26 1. MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic
27
28 dysfunction, and chronic heart failure. *Eur Heart J*. 2008;29(10):1224-1240.
29
30 doi:10.1093/eurheartj/ehn156.
- 31
32 2. Murcia AM, Hennekens CH, Lamas GA, et al. Impact of diabetes on mortality in
33
34 patients with myocardial infarction and left ventricular dysfunction. *Arch Intern*
35
36 *Med*. 2004;164(20):2273-2279. doi:10.1001/archinte.164.20.2273.
- 37
38 3. Krum H, Jelinek M V, Stewart S, et al. *2011 Update to National Heart Foundation*
39
40 *of Australia and Cardiac Society of Australia and New Zealand Guidelines for the*
41
42 *Prevention, Detection and Management of Chronic Heart Failure in Australia,*
43
44 *2006*. Vol 194.; 2011.
45
46 [http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=2149594](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21495941&retmode=ref&cmd=prlinks)
47
48 [1&retmode=ref&cmd=prlinks](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21495941&retmode=ref&cmd=prlinks).
- 49
50 4. Forst T, Hanefeld M, Jacob S, et al. Association of sulphonylurea treatment with
51
52 all-cause and cardiovascular mortality: a systematic review and meta-analysis of
53
54 observational studies. *Diab Vasc Dis Res*. 2013;10(4):302-314.
55
56 doi:10.1177/1479164112465442.
- 57
58 5. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic
59
60 agents in patients with diabetes and heart failure: systematic review. *BMJ*.
2007;335(7618):497. doi:10.1136/bmj.39314.620174.80.
6. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with
a marked increase in mortality in patients with advanced heart failure. *Am Heart J*.
2005;149(1):168-174. doi:10.1016/j.ahj.2004.07.005.
7. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular
outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*.

- 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684.
8. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2013;34(39):3035-3087. doi:10.1093/eurheartj/ehs108.
 9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720.
 10. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. *Eur Heart J*. 2016;37(19):1526-1534. doi:10.1093/eurheartj/ehv728.
 11. McMurray J. EMPA-REG - The "diuretic hypothesis." *J Diabetes Complications*. 2016;30(1):3-4. doi:10.1016/j.jdiacomp.2015.10.012.
 12. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation*. 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887.
 13. Skrtic M, Cherney DZI. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. *Curr Opin Nephrol Hypertens*. 2015;24(1):96-103 8p. doi:10.1097/MNH.0000000000000084.
 14. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081.
 15. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. *Ther Adv Endocrinol Metab*. 2014;5(3):53-61. doi:10.1177/2042018814544153.
 16. Sha S, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Morschel L PD. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2014;16(11):1087. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=cctr&NEWS=N&N=CN-01115818>.
 17. Heise T, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. *Diabetes, Obes Metab*. 2013;15:613-621. doi:10.1111/dom.12073.
 18. Sairaku A, Nakano Y, Kihara Y. Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure. *Int J Cardiol*. 2015;180:42-43. doi:10.1016/j.ijcard.2014.11.138.
 19. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of

- 1
2
3 Kidney Disease in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):323-334.
4 doi:10.1056/NEJMoa1515920.
5
6
7 20. Veldhuisen DJ Van, Ruilope LM, Maisel AS, Damman K. Clinical update
8 Biomarkers of renal injury and function : diagnostic , prognostic and therapeutic
9 implications in heart failure. 2016:2577-2585. doi:10.1093/eurheartj/ehv588.
10
11 21. Lang C, Choy A, Rahman A, Struthers A. Renal effects of low dose prazosin in
12 patients with congestive heart failure. *Eur Heart J*. 1993;14(9):1245-1252.
13 [http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/819/CN-](http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/819/CN-00096819/frame.html)
14 [00096819/frame.html](http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/819/CN-00096819/frame.html).
15
16 22. Goldsmith S, Gilbertson D, Mackedanz S, Swan S. Renal effects of conivaptan,
17 furosemide, and the combination in patients with chronic heart failure. *J Card Fail*.
18 2011;17(12):982-989. doi:10.1016/j.cardfail.2011.08.012.
19
20 23. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport
21 inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care*. 2009;32(4):650-
22 657. doi:10.2337/dc08-1863.
23
24 24. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the
25 beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying
26 hypothesis. *Diabetes Care*. 2016;39(7):1115-1122. doi:10.2337/dc16-0542.
27
28 25. Bebawy JF, Ramaiah VK, Zeeni C, Hemmer LB, Koht A, Gupta DK. The effect of
29 furosemide on intravascular volume status and electrolytes in patients receiving
30 mannitol: an intraoperative safety analysis. *J Neurosurg Anesthesiol*.
31 2013;25(1):51-54. doi:10.1097/ANA.0b013e318269c335.
32
33 26. Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine
34 infusion in postoperative renal failure complicating cardiac surgery. *Ann Thorac*
35 *Surg*. 2000;69(2):501-506. doi:10.1016/S0003-4975(99)01298-9.
36
37 27. Turagam MK, Velagapudi P, Kalra AS, Ramalingam VS, Sinnakirouchenan R,
38 Holley JL. Outcomes of furosemide-mannitol infusion in hospitalized patients with
39 heart failure: an observational single-center cohort study of 122 patients. *Int J*
40 *Cardiol*. 2011;151(2):232-234. doi:10.1016/j.ijcard.2011.06.044.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 3 ___
	2b	All items from the World Health Organization Trial Registration Data Set	_____
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 23 ___
	5b	Name and contact information for the trial sponsor	___ 1 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 23 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ 23 ___

1
2
3 **Introduction**
4

5 Background and 6 rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	___ 5-7 ___
	6b	Explanation for choice of comparators	___ 7 ___
10 Objectives	7	Specific objectives or hypotheses	___ 14-15 ___
12 Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___ 7-8 ___

15
16 **Methods: Participants, interventions, and outcomes**
17

18 Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	___ 2 ___
21 Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	___ 13-14 ___
24 Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	___ 2, 15-17 ___
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	___ 19 ___
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	___ 10 ___
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___ 19 ___
35 Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	___ 2, 15 ___

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_____10_____
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____19_____
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____19_____

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____14_____
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____14_____
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___13-14_____
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____14_____
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____14_____

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____20_____
-------------------------	-----	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------

1				
2				
3		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____
4				
5				
6	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____20_____
7				
8				
9				
10	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	__not included__
11				
12				
13		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____
14				
15		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____
16				
17				
18				
19	Methods: Monitoring			
20				
21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____n/a_____
22				
23				
24				
25				
26		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____
27				
28				
29	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____20_____
30				
31				
32	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____
33				
34				
35				
36	Ethics and dissemination			
37				
38	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____22-23_____
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,	_____
4	amendments		analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
5			regulators)	
6				
7	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	_____ 12 _____
8			how (see Item 32)	
9				
10		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	_____
11			studies, if applicable	
12				
13	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	_____
14			in order to protect confidentiality before, during, and after the trial	
15				
16	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____ 23 _____
17	interests			
18				
19	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	_____
20			limit such access for investigators	
21				
22	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	_____
23	trial care		participation	
24				
25				
26	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	_____
27			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
28			sharing arrangements), including any publication restrictions	
29				
30		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
31				
32		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
33				
34				
35	Appendices			
36				
37	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	_____ not included _____
38	materials			
39				
40	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	_____
41	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
42				

1
2 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
3 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
4 ["Attribution-NonCommercial-NoDerivs 3.0 Unported"](#) license.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

BMJ Open

The Renal and Cardiovascular Effect of Sodium-Glucose co-Transporter 2 (SGLT2) inhibition in combination with Loop Diuretics in Diabetic patients with Chronic Heart Failure (RECEDE-CHF): Protocol for a Randomised Controlled Double-Blind Crossover Trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018097.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Jul-2017
Complete List of Authors:	Mordi, Natalie; University of Dundee Division of Cardiovascular and Diabetes Medicine Mordi, Ify; University of Dundee Division of Cardiovascular and Diabetes Medicine Singh, Jagdeep; University of Dundee Division of Cardiovascular and Diabetes Medicine Baig, Fatima; University of Dundee Division of Cardiovascular and Diabetes Medicine, Division of Cardiovascular and Diabetes Medicine Choy, Anna-Maria; University of Dundee Division of Cardiovascular and Diabetes Medicine McCrimmon, Rory; University of Dundee Division of Cardiovascular and Diabetes Medicine Struthers, Allan; University of Dundee, Division of Cardiovascular and Diabetes Medicine Lang, Chim C.; University of Dundee Division of Cardiovascular and Diabetes Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Diabetes and endocrinology, Pharmacology and therapeutics, Research methods
Keywords:	Sodium-Glucose co-Transporter 2 (SGLT2) Inhibitors, Heart failure < CARDIOLOGY, Diabetes Mellitus, Natriuresis, Diuresis

SCHOLARONE™
Manuscripts

The Renal and Cardiovascular Effect of Sodium-Glucose co-Transporter 2 (SGLT2) inhibition in combination with Loop Diuretics in Diabetic patients with Chronic Heart Failure (RECEDE-CHF): Protocol for a Randomised Controlled Double-Blind Crossover Trial.

Natalie A. Mordi* MRCP n.a.mordi@dundee.ac.uk, **Ify R. Mordi MD MRCP** i.mordi@dundee.ac.uk, **Jagdeep S. S. Singh MRCP** j.x.singh@dundee.ac.uk, **Fatima Baig BSc.** f.z.baig@dundee.ac.uk, **AnnaMaria Choy FRCP FACC** a.choy@dundee.ac.uk, **Rory J. McCrimmon MD** r.mccrimmon@dundee.ac.uk, **Allan D. Struthers MD FRCP** a.d.struthers@dundee.ac.uk, **Chim C. Lang MD FACC** c.c.lang@dundee.ac.uk

***Correspondence:**

Dr Natalie A. Mordi

Division of Molecular and Clinical Medicine, Mailbox 2, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK

Phone: +44-1382-383013

Email: n.a.mordi@dundee.ac.uk

Short title: SGLT2 Inhibition in combination with diuretics in heart failure

Word Count: Abstract: 298. Excluding title page, abstract, figures and references: 5075

Key words: Heart failure, diabetes mellitus, sodium-glucose co-transporter 2 (SGLT2) inhibitors, natriuresis, diuresis

Version 2.0. 9th July 2017

ABSTRACT

Introduction: Type 2 diabetes (T2D) and heart failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium-glucose co-transporter 2 (SGLT2) inhibitors and their use in patients with HF. Data on the effect of SGLT2 inhibitor use with diuretics is limited. We hypothesise that SGLT2 inhibition may augment the effects of loop diuretics.

Methods and Analysis: To assess the effect of SGLT2 inhibitors when used in combination with a loop diuretic, the RECEDE-CHF trial is a single centre, randomised double-blind, placebo-controlled, crossover trial conducted in a secondary care setting within NHS Tayside, Scotland.

34 eligible participants, aged between 18 to 80 years, with stable T2D and CHF will be recruited. Renal physiological testing will be performed at two points (week 1 and week 6) on each arm to assess the effect of 25mg empagliflozin, on the primary and secondary outcomes. Participants will be enrolled in the trial for a total period between 14 to 16 weeks.

The primary outcome will assess the effect of empagliflozin versus placebo on urine output. The secondary outcomes are to assess the effect of empagliflozin on glomerular filtration rate, cystatin C, urinary sodium excretion, urinary protein/creatinine ratio, and urinary albumin/creatinine ratio when compared to placebo.

We hypothesise that the benefits of SGLT2 inhibitors extend beyond those of their metabolic (glycaemic parameters and weight loss) and haemodynamic parameters; that the effects of SGLT2 inhibitors as an osmotic diuretic and on natriuresis may underlie the cardiovascular and renal benefits demonstrated in the recent EMPA-REG study.

Ethics and Dissemination: Ethics approval was obtained by the East of Scotland Research Ethics Service. Results of the trial will be submitted for publication in a peer-reviewed journal.

Registration Details: Prospective registration will be obtained via clinicaltrials.gov: before the enrolment of patients.

ARTICLE SUMMARY**STRENGTHS AND LIMITATIONS**

- **Original proof of concept study that aims to explore the effect on diuresis and natriuresis of SGLT2 inhibitors in combination with furosemide**
- **Randomised, double-blind crossover study design**
- **Small, single centre study**
- **High participant dropout rate has been factored into power calculations**
- **Aims to shed light on the mechanism of the cardiovascular benefits seen in EMPA-REG OUTCOME trial**

BACKGROUND

Chronic heart failure (CHF) and type 2 diabetes (T2D) frequently coexist. In population-based studies and in CHF trials, the prevalence of T2D among patients with symptomatic HF is estimated to be between 12% and 41%.¹ T2D has consistently been shown to be an independent predictor of increased morbidity and mortality in patients with CHF.²

For most patients, metformin is the first choice anti-diabetic drug in all T2D patients including those with coincidental HF.³ However, metformin alone is often not enough to keep glycaemia under control and there is a frequent need for a second line anti-diabetic drug in HF patients. Sulphonylureas (SU) are commonly prescribed in T2D however they are associated with weight gain and hypoglycaemia, while there remain concerns that SUs may increase all-cause and cardiovascular (CV) mortality,⁴ although this link is not fully established. Glitazones are contra-indicated in New York Heart Association (NYHA) III or IV HF, while their role in milder degrees of HF remains to a certain extent controversial with some observational studies indicating increased hospitalisation or readmission due to HF.⁵ Insulin use has also been associated with increased mortality in patients with CHF.⁶ More recent agents such as the DPP-IV inhibitors have also, disappointingly, failed to show cardiovascular benefit with some concerns raised following the publication of SAVOR-TIMI-53, that they increased HF hospitalisations, although these trials have only been of short duration⁷ and may not apply to all DPP-IV inhibitors. Therefore, it can be concluded that therapeutic options in DM and HF limited due to a lack of evidence-based guidelines on the optimal management of such patients. Indeed, international guidelines recognize the evidence gap on the safety and efficacy of drugs used to treat DM in patients with HF as well as the need for agents that will both improve overall glycaemic control and HF outcomes.⁸

SGLT2 Inhibitors and HF

SGLT2 inhibitors are licensed for use in patients with T2D. These oral anti-diabetic agents achieve their effects by blocking the low affinity, high capacity Type 2 Sodium-Glucose Linked Co-Transporter (SGLT2), predominantly found in the proximal convoluted tubules of the kidneys, thus causing glycosuria. The recent landmark

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EMPA-REG outcome study reported a striking 35% relative risk reduction in HF hospitalisations with empagliflozin may provide supportive evidence for beneficial effects of SGLT2 inhibition in the setting of CHF.⁹ A recent analysis of the EMPA-REG study showed that empagliflozin reduced HF hospitalization and cardiovascular death, with a consistent benefit in patients with and without baseline HF.¹⁰

The effect of empagliflozin on HF hospitalization or CV death and on all-cause hospitalization was observed very early and was sustained throughout the trial. This suggests that the benefit was not driven by an effect on atherosclerosis. The mechanisms behind the effects of empagliflozin on HF and CV death are unknown. It has been hypothesised that the benefits of SGLT2 inhibitors extend beyond those of the glycaemic parameters of weight loss as promoted by glycosuria, but the effects of SGLT2 inhibitors on non-glycaemia parameters including blood pressure lowering as well as osmotic diuretic and natriuretic effects which may underlie the cardiovascular (and renal) benefits.^{11,12}

Renal effects of SGLT2 inhibition and co-prescribing with Loop Diuretics

The renal effects of SGLT2 inhibitors are attracting much recent interest as they may confer renal protection.^{13,14} There is data to support the potential for direct renoprotective actions arising from SGLT2 inhibition including actions to attenuate T1D associated hyperfiltration through an effect on tubulo-glomerular (TG) feedback which may have renal-protective effects by decreasing glomerular hydrostatic pressure.^{13,14} SGLT2 inhibition has also been shown to attenuate tubular hypertrophy and reduce the tubular toxicity of glucose.¹⁵ They may also have indirect renoprotective effects through its blood pressure lowering effects and glycaemia lowering effects which could decrease the renal inflammatory and fibrotic response by blocking glucose entry into the cell.¹⁵ Consequently, there are now several on-going SGLT2 inhibitor renal outcome trials in T2D, including the CANVAS-R trial (clinicaltrials.gov identifier NCT01989754) and the CREDENCE trial (clinical trials.gov identifier NCT02065791). However, neither trial specifically looks at T2DM patients with CHF.

Studies relating to diuresis in the context of SGLT2 inhibitors are surprisingly sparse.¹² Previous studies with empagliflozin and canagliflozin have demonstrated a 24 hour

1
2
3 urinary increase by 300 ml/day after day 1 of treatment but that the daily urinary volume
4 returned to baseline after several weeks.^{16,17} One Japanese case report however, in a
5 non-diabetic patient, described successful treatment of fluid overload that was initially
6 resistant to diuretic therapy, with 5 days of treatment of 50mg ipragliflozin.¹⁸
7
8
9

10
11 In post-hoc analysis of EMPA-REG OUTCOME, Fitchett et al. reported reduced use of
12 furosemide in patients on the empagliflozin arm, suggesting that these patients reached
13 a relative state of euvolaemia.^{10,12} Heerspink et al. highlighted that, volume depletion
14 and associated use of loop diuretic is long associated with a pre-renal cause of acute
15 kidney injury, and a decrease in loop diuretic may also be relevant in light of the
16 reductions in acute kidney injury, acute renal failure and chronic kidney disease
17 progression endpoints.^{12,19}
18
19
20
21
22
23

24 The renal effects of SGLT2 inhibitors in combination with furosemide in T2D with CHF
25 are not known but given the relative frequency of both co-morbidities they are likely to
26 be prescribed concurrently. This underscores the need for a trial to provide detailed
27 acute and long-term information regarding the renal effects of SGLT2 inhibition in
28 combination with loop diuretics, in T2D patients with stable CHF.
29
30
31
32

33 We hypothesize that SGLT2 inhibitors may be able to address the issue of diuretic
34 resistance and may augment the diuretic effects of furosemide in patients with T2D and
35 CHF.
36
37
38

39 We will recruit diabetic HF patients taking stable doses of furosemide, or, alternative
40 loop diuretics, with eGFR greater than 45ml/min/1.73m². This trial will, with careful
41 monitoring, begin the process of uncovering the unrealised potential of this new class of
42 drug which, for the reasons outlined above, is poised to become the 2nd line anti-
43 diabetic agent of choice in HF patients.
44
45
46
47
48
49
50

51 **METHODS: PARTICIPANTS, INTERVENTIONS, AND OUTCOMES**

52 **Trial design**

53
54
55
56
57
58
59
60

1
2
3 The RECEDE-CHF Trial is a single centre phase IV, randomised, double-blind, placebo-
4 controlled, crossover, trial conducted in NHS Tayside, Scotland to compare the SGLT2
5 inhibitor empagliflozin 25mg, to placebo. Participants will be enrolled in the trial for a
6 period of between 14 to 16 weeks. The trial design is summarised in **Figure 1 and**
7
8
9
10 **Table 1.**
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. RECEDE-CHF Trial Protocol

Visit	Visit 1* Screening	Visit 2* Baseline/ Randomisation	Visit 3	Visit 4 (Tele Visit)	Visit 5	Two week wash- out period	Visit 6	Visit 7	Visit 8 (Tele Visit)	Visit 9 (Final Visit)****
Week	Up to 4 weeks pre visit 2	Day 0	Day 3 (+/-2 days)	Week 3 (+/- 3 days)	Week 6 (+/- 3 days)		Week 9 (+/- 3 days)	Week 9 + 3 days (+/- 2 days)	Week 12 (+/- 3 days)	Week 15 (+/- 3 days)
Informed Consent	X									
Inclusion/Exclusion Criteria	X	X					X	X		
Past Medical History	X									
Demographics	X				X		X			X
Vital Signs	X	X	X		X		X	X		X
Safety Bloods	X	X	X		X		X	X		X
Research Bloods		X	X		X		X	X		X
Genetic Blood Sample**		X								
uPCR/uACR		X	X		X		X	X		X
Urine Pregnancy Test***	X	X	X		X		X	X		X
24 urinary collection			X		X			X		X
Renal Physiology Test			X		X			X		X
Drug Dispensing		X					X			
AE assessment		X	X	X	X		X	X	X	X
Record/Review Meds	X	X	X	X	X		X	X	X	X
Drug Compliance			X	X	X			X	X	X

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Check										
-------	--	--	--	--	--	--	--	--	--	--

Visits 1 and Visits 2 combined into one visit where able *

Genetic Blood Sample** - only to be taken if participant consent given.

Urine Pregnancy Test*** - testing on females of childbearing potential or who do not abstain from sex or use effective contraception.

Final Visit**** - if the participant wishes to withdraw prematurely or at the PI's discretion, all study procedures will be conducted as though the final visit, if participant agrees.

uPCR/uACR urine protein/creatinine ratio, urine albumin/creatinine ratio

peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

At the screening visit, following informed consent, an initial medical history and clinical examination will be performed and concomitant medication will be recorded. Participants will have bloods taken for safety analysis and vital signs will be checked to confirm eligibility prior to enrolment. An assessment of suitability of the trial for the potential participant will be undertaken by the principal investigator (PI) or medically qualified delegate.

Should the participant meet the inclusion criteria and have no exclusion criteria identified, they will return for the baseline/randomisation visit at the Clinical Research Centre (CRC), Ninewells Hospital, Dundee, within four weeks post screening visit. Where able the screening visit and randomisation visits will be combined.

At the randomisation visit participants will undergo safety blood tests, vital signs and study medication will be dispensed (either empagliflozin 25mg or placebo).

Participants will continue on study medication, empagliflozin 25mg or placebo, once daily, for a period of 6 weeks. Participants will be educated on the symptoms of hypoglycaemia and given a written action plan on how to manage it in the unlikely event that it occurs.

Participants will return to the CRC 3-days (± 2 days) post-randomisation, for a study day where they will have safety and research bloods drawn, vital signs recorded and will undergo renal physiological tests (RPT). Further details of these RPT are described below.

Participants will then return again at week 6 for a study day where they will undergo RPT again, safety and research bloods will be drawn and vital signs recorded. Participants will terminate study drug, either empagliflozin 25mg or placebo, at this visit and will return to the CRC at the end of the two week wash out period (week 9).

At week 9, participants will have safety and research bloods drawn, vital signs recorded, new study medication dispensed. The RPT will then be repeated at the same intervals, at week 9 + 3 days (± 2 days) and at week 14 for the final study day. Participants will then terminate study drug, either empagliflozin 25mg or placebo.

Study population

34 patients with underlying diabetes and well-controlled chronic heart failure (CHF) will be recruited from a range of sources. The local Tayside database of the systems biology study to tailored treatment in chronic heart failure (BIOSTAT) database consisting of around 1800 patients with HF who have previously consented to be approached for future research. The investigators may also recruit from NHS Tayside diabetes and/or heart failure clinics, SHARE The Scottish Health Research Register, where participants have pre-consented to be invited for research. It is anticipated it will take up to 18 months to recruit the 34 patients for randomisation with approximately 80-100 being consented into the screening trial. We anticipate a screen failure rate of 20% and a drop-out rate of 35% after recruitment based on previous heart failure studies within this research group and the high intensity of the Renal Physiology Test days which will occur on 4 occasions in total.

Eligibility

Patients will be eligible if they:

- Aged 18 to 80 years with previously diagnosed Type 2 Diabetes Mellitus.
- Are diagnosed with NYHA Functional class II-III HF with prior echocardiographic evidence of LVSD.
- On stable doses of furosemide, or alternative loop diuretic for one month
- Stable Type 2 Diabetes (HbA1c, in the last 3 months, of 10.0% \geq and \geq 6.5%)
- Point of Care BNP > 100 pg/ml
- eGFR \geq 45 ml/min/1.73m²
- Have stable HF symptoms for at least three months prior to consent
- On stable HF therapy for at least three months prior to consent
- Have not been hospitalised for HF for at least three months prior to consent

Patients will be excluded if they:

- A diagnosis of chronic liver disease and/or liver enzymes that are twice the upper limit of normal
- Systolic BP of <95mmHg at screening visit.

- eGFR < 45 ml/min/1.73m²
- Patients on thiazide diuretics
- Malignancy (receiving active treatment) or other life threatening disease.
- Pregnant or lactating women
- Patients with difficulty in micturition e.g. severe prostate enlargement
- Patients who have participated in any other clinical trial of an investigational medicinal product within 30days
- Patients who are unable to give informed consent
- Any other reason considered by the physician to be inappropriate for inclusion.

Randomisation and treatment allocation

After successful screening for eligibility and safety, participants will be randomised to either empagliflozin 25mg/placebo or placebo/empagliflozin 25 mg in a double blind fashion in this crossover study.

The double blind medication (empagliflozin or placebo) will be prepared, packaged and labelled by our onsite clinical trials pharmaceutical manufacturer. Randomisation will be carried out by our dedicated clinical trials pharmacy using block randomisation. They will use a validated randomisation program and will securely backup both the randomisation seed and the randomisation allocation and have it available in the onsite 24-h emergency unblinding facility.

Participants will be given blinded medication. At the randomisation visit they will be dosed with either empagliflozin 25mg (6 weeks) or matched placebo (6 weeks) to continue once daily, with a 2-week washout period between each arm. Participants and their bloods (including urea & electrolytes, liver function tests, and full blood count) will be monitored as per trial schedule and medication stopped if concerns arise. If the trial drug needs to be stopped due to intolerance or adverse events, they will remain in the trial in order to do an "intention to treat" analysis.

Trial outcomes

1
2
3 The primary aim/objectives will be to assess whether empagliflozin (SGLT2 Inhibitor)
4 can augment the diuretic effects of loop diuretics in diabetic patients with mild CHF with
5 left ventricular systolic dysfunction (LVSD), as measured by urinary volume, compared
6 to placebo.
7
8
9

10
11 The secondary aims/objectives are to assess the effect of empagliflozin (SGLT2
12 inhibitor) on natriuresis when used with loop diuretics in diabetic patients with mild CHF
13 with LVSD as measured by urinary sodium excretion, to measure the safety of add-on
14 SGLT2 inhibitor therapy versus placebo on top of loop diuretics as measured by serum
15 creatinine and eGFR, to assess effects of empagliflozin on protein/creatinine ratio,
16 albumin/creatinine ratio and on the renal biomarker, cystatin C.²⁰
17
18
19
20

21 **Renal Physiology Tests**

22
23 Patients will attend the Clinical Research Centre (CRC), Ninewells, Dundee on 4
24 separate study days (2 while in each arm of the trial). On each study day, patients will
25 present themselves to our CRC, following an overnight fast. Two days before presenting
26 to the CRC, patients will be required to follow a 2gram sodium and 2L fluid/day
27 controlled diet. A 24-hour urinary collection will be requested the day prior to
28 presentation at the CRC for urinary volume and sodium. Patients will be asked to take
29 their morning usual medications except their investigational medicinal product
30 (empagliflozin or placebo) and furosemide (or equivalent loop diuretic).
31
32
33
34
35
36
37
38

39 An intravenous (IV) cannula will be placed in each arm for subsequent infusion and
40 blood sampling. Bloods will be drawn for measurement of plasma NT-proBNP and
41 cystatin C using standard protocols. A 15 ml/kg oral water load will be administered over
42 a 15 min period. Thereafter, at 30 min intervals, patients will be requested to void urine
43 until the end of the study period. The volume of urine passed will be measured and an
44 aliquot stored for later analysis. On each occasion, the volume of urine passed will be
45 measured, and an equal volume of water given to drink. In this way, a steady state
46 diuresis will be established over approximately over 3 hours, avoiding the need for
47 catheterisation. The last 30 min urinary collection during this stabilization period will be
48 taken as baseline. At + 150 minutes, each patient will receive an oral tablet of either
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 empagliflozin 25mg or placebo. At + 210 minutes, patients will be given a bolus of IV
4 furosemide at half their total daily dose.
5
6

7 Heart rate and blood pressure will be displayed continuously on an ECG oscilloscope
8 and the blood pressure measured every 60 min. Venous blood will be obtained at the
9 midpoint of each clearance period for measurement of serum sodium, osmolality and
10 creatinine. **Figure 2** outlines the protocol for the RPT test day.
11
12
13

14
15 IV furosemide will be administered to eliminate variable furosemide gut absorption and
16 for practical reasons to complete the study within the set time frame due to the reduced
17 time for the peak onset of diuretic effect with IV administration.
18
19

20
21 Data on the effect of SGLT2 inhibitors and the participant's usual oral diuretic regime
22 will be gained by the collection of 24 urinary samples on the days before the RPT.²¹
23
24

25 **Tolerability**

26
27
28 We will monitor for tolerability of the study medication. One of the inevitable side effects
29 of empagliflozin and other SGLT2 inhibitors with the promotion of glycosuria is urinary
30 tract infections. This typically presents itself as genital mycotic infection, typically
31 *Candida albicans*, which is usually straightforward to treat. However, if patients were to
32 present with infection unresponsive to standard treatment then the trial drug would be
33 discontinued. They will also be warned of the side effects including hypoglycaemia with
34 a written action plan on how to recognise and treat in the unlikely event of a
35 hypoglycaemic episode
36
37
38
39
40
41
42

43 **Sample size and power calculations**

44
45 Power calculations were performed by the University of Dundee's Senior Medical
46 Statistician and are based on our previous data in patients with CHF²¹ as well as more
47 contemporary data.²² The sample size is based on the mean furosemide-induced
48 urinary volume and sodium excretion of 920 ml/hr (SD=250) and 300 μ mol/min
49 (SD=60) respectively. A 20% increase is expected in these parameters following SGLT2
50 inhibition. This increase in urinary volume is based on published percentage increases
51 in urinary volume in T2D patients that range from 11%-33% depending on the dose of
52
53
54
55
56
57
58
59
60

1
2
3 the SGLT2 inhibitor as shown by List and colleagues²³ in the available data with
4 dapagliflozin (dapagliflozin 2.5 mg: 11% increase in 24-hr urine volume; dapagliflozin 5
5 mg: 22% 11% increase in 24-hr urine volume; dapagliflozin 10 mg: 24% 11% increase
6 in 24-hr urine volume; dapagliflozin 20 mg: 27% 11% increase in 24-hr urine volume
7 and dapagliflozin 50 mg: 33% 11% increase in 24-hr urine volume). There is no data of
8 SGLT inhibition together with loop diuretics. As described previously the Japanese case
9 report of a diuretic resistant HF patient in whom fluid overload was successfully treated
10 with the SGLT2 inhibitor, ipragliflozin, where a striking 50% increase in urinary volume
11 (following treatment with 50 mg daily of oral ipragliflozin for 5 days) was described.¹⁸
12 Based on the above, it was determined that a 20% increase in furosemide induced
13 increase in urinary volume and sodium excretion will be reasonable.
14
15
16
17
18
19
20
21
22

23 With an alpha 0.05 and power of 90%, 22 participants per arm are required, assuming
24 35% drop out. Since this trial is using an AB/BA crossover design, a total of 34
25 participants will be required, as each participant will be exposed to both arms of the trial.
26 The rationale for the high dropout rate, is due to the high intensity renal physiological
27 tests that will occur on 4 occasions for the participants, from 0730 hrs to 1400 hrs we
28 feel that anything less than a 35% drop out rate would be conservative.
29
30
31
32
33
34
35
36

37 **METHODS: DATA COLLECTION, MANAGEMENT, AND ANALYSIS**

38 **Data Collection**

39 The data will be collected by the PI or delegate on a paper case report form (CRF) with
40 subsequent transcription to an electronic CRF. Electronic storage will be in an
41 encrypted form on a password protected device. The medical notes will act as source
42 data for past medical history and blood results. Any data relating to general medical
43 history will be documented in the notes.
44
45
46
47
48
49
50

51 **Statistical Plan**

52 Participants will be allocated to treatment groups at random. Descriptive statistics will be
53 calculated for all data and reported as mean (SD) for continuous data and N (%) for
54 categorical data. For statistical evaluation of repeated measurements, analysis of
55
56
57
58
59
60

1
2
3 variance will be used. $P < 0.05$ will be taken as the level of statistical significance. The
4 study is powered based on the primary outcome. In order to examine differences in
5 patient characteristics between study groups, between-group comparisons will be
6 assessed using independent t-tests or analysis of variance (ANOVA). Within-group
7 comparisons will be conducted using paired sample t-tests or repeated measures
8 ANOVA if data meet parametric assumptions.
9
10
11
12
13

14 15 16 17 **METHODS: MONITORING**

18 19 **Data Monitoring**

20
21
22 A Data Monitoring Committee is not considered necessary as this is a relatively small
23 trial. Close supervision of the PI/Clinical Research Fellow will be conducted by an
24 experienced Chief Investigator supported by a senior trial manager from the Tayside
25 Clinical Trials Unit (TCTU).
26
27
28

29
30 The purposes of trial monitoring are to verify that the rights and well-being of human
31 subjects are protected, the reported trial data are accurate, complete and verifiable from
32 source documents and the conduct of the trial is in compliance with the currently
33 approved protocol/amendment(s), with Good Clinical Practice (GCP), and with the
34 applicable regulatory requirement(s). The Sponsor will determine the appropriate extent
35 and nature of monitoring for the trial and will appoint appropriately qualified and trained
36 monitors. The monitor will communicate any monitoring findings to both the CI and PI
37 and the Sponsor.
38
39
40
41
42
43
44

45 **Identifying, Recording and Reporting Adverse Events**

46
47 Participants should be instructed to contact a member of the trial team at any time after
48 consenting to join the trial if any of the above symptoms develop. All reported adverse
49 events (AEs) that occur after joining the trial will be recorded in detail in the CRF AE log.
50 In the case of an AE, the Investigator should initiate the appropriate treatment according
51 to their medical judgement. Participants with AEs present at the last visit must be
52 followed up until resolution of the event.
53
54
55
56
57
58
59
60

1
2
3 The CI or delegate will ask about the occurrence of AEs and hospitalisations at every
4 visit during the trial. AEs will be recorded on the AE Log in the CRF. Serious adverse
5 events (SAEs) will be submitted on an SAE form to the TASC Pharmacovigilance
6 Section within 24 hours of becoming aware of the SAE. SAEs will be initially assessed
7 for causality and expectedness by the Investigator. The Sponsor will make the definitive
8 assessment on expectedness. The evaluation of expectedness will be made based on
9 the knowledge of the reaction and the relevant product information (Summary of
10 Product Characteristics).

11 12 13 14 15 16 17 18 **Confidentiality**

19
20 All laboratory specimens, evaluation forms, reports, and other records will be identified
21 in a manner designed to maintain participant confidentiality. All records will be kept in a
22 secure storage area with limited access to trial staff only. Clinical information will not be
23 released without the written permission of the participant, except as necessary for
24 monitoring and auditing by the Sponsor, its designee or Regulatory Authorities. The CI
25 and trial staff will not disclose or use for any purpose other than performance of the trial,
26 any data, record, or other unpublished, confidential information disclosed to those
27 individuals for the purpose of the trial. Prior written agreement from the Sponsor or its
28 designee will be obtained for the disclosure of any said confidential information to other
29 parties.

30 31 32 33 34 35 36 37 38 **ETHICS AND DISSEMINATION**

39
40 Ethics approval was obtained by the East of Scotland Research Ethics Service. This
41 trial has been funded by the British Heart Foundation who have peer reviewed the grant
42 application. Additional peer review of the protocol occurs via the Sponsorship
43 Committee.

44
45 The clinical trial report will be used for publication and presentation at scientific
46 meetings. Trial investigators have the right to publish orally or in writing the results of
47 the trial.

48
49 Prospective registration will be obtained via clinicaltrials.gov before the enrolment of
50 patients.

1
2
3 Should any protocol modifications arise, these will be decided by the CI on discussion
4 with the PI, which would will be escalated to the Trial Sponsor, who will decide if further
5 notification to the relevant authorities is required.
6
7

8 9 **Access to data**

10
11 Ownership of the data arising from this trial resides with the trial team and their
12 respective employers. On completion of the trial, the trial data will be analysed and
13 tabulated, and a clinical trial report will be prepared.
14
15
16

17 18 **DISCUSSION**

19
20 SGLT2 inhibition is an innovative strategy for the management of T2D, where
21 historically, anti-hyperglycemic interventions have focused on restoring B-cell activity,
22 insulin sensitivity, or tissue glucose uptake to normalise plasma glucose levels.¹²
23
24

25
26 In this proof of concept trial, we hypothesise that the benefits of SGLT2 inhibitors extend
27 beyond those of their metabolic (glycaemic parameters and weight loss) and
28 haemodynamic parameters; that the effects of SGLT2 inhibitors as an osmotic diuretic
29 and on natriuresis may underlie the cardiovascular and renal benefits.
30
31
32

33
34 Whilst the encouraging renal and cardiovascular outcomes demonstrated in EMPA-
35 REG might be explained by the modest but cumulative effect of blood pressure lowering
36 (mean reduction in systolic BP ~ 3 mmHg), HbA1c reduction (0.3%), and weight
37 reduction (~ 1kg), it is difficult to ignore the possibility that an additional mechanism may
38 also be at work.^{19,24} For example, Mudaliar et al hypothesise that empagliflozin may also
39 improve renal fuel energetics and efficiency, providing more energy efficient oxygen
40 consumption and thereby potentially less hypoxic stress on the diabetic heart and
41 kidney.²⁴
42
43
44
45
46
47

48
49 The SGLT2 inhibitors may also have indirect renoprotective effects through its blood
50 pressure lowering effects and glycaemia lowering effects which could decrease the
51 renal inflammatory and fibrotic response by blocking glucose entry into the cell.¹⁵
52
53 Consequently, there are now several on-going SGLT2 inhibitor renal outcome trials in
54 T2D, including the CANVAS-R trial (clinicaltrials.gov identifier NCT01989754) and the
55
56
57
58
59
60

1
2
3 CREDENCE trial (clinical trials.gov identifier NCT02065791). However, neither trial
4 specifically looks at T2D patients with CHF.
5
6

7 We have also described that SGLT2 inhibitors may augment the effect of loop diuretics.
8 It is noteworthy that osmotic diuretics such as mannitol have been used alone or in
9 combination with loop diuretics such as furosemide to promote diuresis in patients
10 undergoing intra-cranial surgery²⁵ and in the postoperative period to prevent acute
11 kidney injury.²⁶ In CHF, mannitol was reported to promote effective diuresis in a single
12 centre study in the US.²⁷ Importantly, in all these settings, mannitol, which is a potent
13 osmotic diuretic when used in combination with furosemide, was shown to be safe and
14 did not result in renal failure or electrolyte disturbances.
15
16
17
18
19
20
21

22 By detailing urinary volumes and sodium excretion via renal physiological tests at two
23 points 3 days and 6 weeks into the investigational medicinal product, the trial's primary
24 aims to assess the change to these markers representative of diuresis in patients on
25 empagliflozin and when compared to placebo. The effects on natriuresis, proteinuria,
26 albuminuria, cystatin C will also be studied as will the safety of add-on SGLT2 inhibition
27 versus placebo.
28
29
30
31
32

33 **LIMITATIONS**

34
35
36 Whilst power calculations have been conducted to calculate the sample size, an
37 obvious limitation is that this is a small single centre trial. The proposed trial will require
38 participants on four occasions to undergo detailed renal physiological tests, (from 0730-
39 1400) as such a dropout rate has been factored in of 35%.

40
41
42
43 Heart failure is a dynamic disease; its natural history is one of flux as the patient's
44 intravascular volume changes, their loop diuretic requirement may also fluctuate.
45 However, as stipulated on the inclusion criteria, we will be taking patients with heart
46 failure with evidence of previous LVSD, but with stable symptoms and medications for 3
47 months, who have not had a hospital admission for heart failure within this same time
48 frame.
49
50
51
52
53

54 **CONCLUSION**

1
2
3 Whilst the osmotic diuretic hypothesis¹¹ is frequently discussed in relation to the renal
4 and cardiovascular outcomes with SGLT2 inhibition, literature on the effect of SGLT2
5 inhibitors on diuresis is currently limited. At time of writing, no studies have been
6 performed to assess the effect of loop diuretics when used in combination with SGLT2
7 inhibitors. This proof of concept trial will aim to shed light on the mechanism of the
8 cardiovascular and renal outcomes demonstrated in the recent EMPA-REG study by
9 documenting the influence of the SGLT2 inhibitors when used in combination with a
10 loop diuretic on urinary volumes and natriuresis when compared to placebo.
11

12 Further intent of this proposed study is to obtain data that might be relevant to the
13 design of future studies in which SGLT2 inhibitors may be considered as an adjunctive
14 agent to loop diuretics in patients who experience diuretic resistance. Although data is
15 currently limited, since HF and T2D are frequent co-morbidities, it is probable that
16 physicians may find patients requiring both SGLT2 inhibitor therapy and furosemide
17 concurrently. Only by studying this, can these fundamental issues be addressed and,
18 perhaps, inspire a change in practise.
19

20 21 22 23 24 25 26 27 28 29 30 31 **List of abbreviations**

32
33
34 T2D: type 2 diabetes, HF: heart failure, CHF: chronic heart failure, EASD: European
35 Association for the Study of Diabetes, ADA: American Diabetes Association, SU:
36 sulphonylureas, CV: cardiovascular, NYHA: New York Heart Association, DPP4
37 inhibitors: Dipeptidyl peptidase-4, SGLT2 inhibitors: Sodium-Glucose Linked co-
38 Transporter 2 inhibitors, LVSD: left ventricular systolic dysfunction, LV: left ventricular,
39 TG: tubulo-glomerular, eGFR: estimated glomerular filtration rate, CRC: Clinical
40 Research Centre, Ninewells Hospital, Dundee, UK, RPT: renal physiological tests,
41 EFSD: European Foundation for the Study of Diabetes, PI: principal investigator,
42 BIOSTAT: A systems BIOlogy Study to TAIlored Treatment in Chronic Heart Failure,
43 SHARE: The Scottish Health Research Register, CI: Chief Investigator, GCP: Good
44 Clinical Practice, SD: Standard Deviation, ANOVA: analysis of variance, TCTU: Tayside
45 Clinical Trials Unit, AEs: adverse events, SAEs: Serious adverse events, TASC:
46 Tayside Medical Science Centre, SmPC: Summary of Product Characteristics.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DECLARATIONS

Ethics approval and consent to participate

This protocol has been reviewed by the East of Scotland Research Ethics Service. Reference number 16/ES/0137.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

ADS has received research support from Astra Zeneca, as well as lecture and consulting fees also from Astra Zeneca. CCL has received research support and consulting fees from Novartis, research support, lecture fees, and consulting fees from AstraZeneca, lecture fees from Merck Sharp & Dohme, and research support from Pfizer and Sanofi. AMC has received research support from St Jude Medical, lecture fees for Daiichi Sankyo, travel support from Boston Scientific, Biotronik, Medtronic, St Jude Medical. RJM has served on advisory boards for Novo Nordisk, Sanofi, Lilly. Rest of the authors declare no competing interests.

Funding

The RECEDE-CHF trial is funded by the British Heart Foundation (BHF grant number: 807998). NAM is a BHF funded clinical research fellow.

Authors' contributions

NAM participated in the design of the study, data collection and drafting the manuscript. IM and JSS participated in the design of the study and reviewing the manuscript. FB and AMC read and approved the final manuscript. RJM and ADS participated in study design and coordination as well as reading and approving the final manuscript. CCL conceived the study, participated in its design and helped draft the manuscript.

Acknowledgements

Our gratitude to all members of staff within the department of Division of Cardiovascular and Diabetes Medicine at the University of Dundee, and the team at the Clinical Research Centre, University of Dundee, Ninewells Hospital and Medical School, UK.

REFERENCES

1. MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. *Eur Heart J*. 2008;29(10):1224-1240. doi:10.1093/eurheartj/ehn156.
2. Murcia AM, Hennekens CH, Lamas GA, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. *Arch Intern Med*. 2004;164(20):2273-2279. doi:10.1001/archinte.164.20.2273.
3. Krum H, Jelinek M V, Stewart S, et al. *2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the Prevention, Detection and Management of Chronic Heart Failure in Australia, 2006*. Vol 194.; 2011. <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21495941&retmode=ref&cmd=prlinks>.
4. Forst T, Hanefeld M, Jacob S, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. *Diab Vasc Dis Res*. 2013;10(4):302-314. doi:10.1177/1479164112465442.
5. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. *BMJ*. 2007;335(7618):497. doi:10.1136/bmj.39314.620174.80.
6. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. *Am Heart J*. 2005;149(1):168-174. doi:10.1016/j.ahj.2004.07.005.
7. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684.
8. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2013;34(39):3035-3087. doi:10.1093/eurheartj/eh108.
9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720.

10. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. *Eur Heart J*. 2016;37(19):1526-1534. doi:10.1093/eurheartj/ehv728.
11. McMurray J. EMPA-REG - The “diuretic hypothesis.” *J Diabetes Complications*. 2016;30(1):3-4. doi:10.1016/j.jdiacomp.2015.10.012.
12. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation*. 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887.
13. Skrtic M, Cherney DZI. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. *Curr Opin Nephrol Hypertens*. 2015;24(1):96-103 8p. doi:10.1097/MNH.0000000000000084.
14. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081.
15. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. *Ther Adv Endocrinol Metab*. 2014;5(3):53-61. doi:10.1177/2042018814544153.
16. Sha S, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Morschel L PD. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2014;16(11):1087. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=cctr&NEWS=N&N=CN-01115818>.
17. Heise T, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. *Diabetes, Obes Metab*. 2013;15:613-621. doi:10.1111/dom.12073.
18. Sairaku A, Nakano Y, Kihara Y. Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure. *Int J Cardiol*. 2015;180:42-43. doi:10.1016/j.ijcard.2014.11.138.
19. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920.
20. Veldhuisen DJ Van, Ruilope LM, Maisel AS, Damman K. Clinical update Biomarkers of renal injury and function : diagnostic , prognostic and therapeutic implications in heart failure. 2016:2577-2585. doi:10.1093/eurheartj/ehv588.
21. Lang C, Choy A, Rahman A, Struthers A. Renal effects of low dose prazosin in patients with congestive heart failure. *Eur Heart J*. 1993;14(9):1245-1252.

1
2
3 <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/819/CN-00096819/frame.html>.

- 6
7 22. Goldsmith S, Gilbertson D, Mackedanz S, Swan S. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. *J Card Fail*. 2011;17(12):982-989. doi:10.1016/j.cardfail.2011.08.012.
- 10
11 23. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care*. 2009;32(4):650-657. doi:10.2337/dc08-1863.
- 14
15 24. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. *Diabetes Care*. 2016;39(7):1115-1122. doi:10.2337/dc16-0542.
- 18
19 25. Bebawy JF, Ramaiah VK, Zeeni C, Hemmer LB, Koht A, Gupta DK. The effect of furosemide on intravascular volume status and electrolytes in patients receiving mannitol: an intraoperative safety analysis. *J Neurosurg Anesthesiol*. 2013;25(1):51-54. doi:10.1097/ANA.0b013e318269c335.
- 22
23 26. Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. *Ann Thorac Surg*. 2000;69(2):501-506. doi:10.1016/S0003-4975(99)01298-9.
- 27
28 27. Turagam MK, Velagapudi P, Kalra AS, Ramalingam VS, Sinnakirouchenan R, Holley JL. Outcomes of furosemide-mannitol infusion in hospitalized patients with heart failure: an observational single-center cohort study of 122 patients. *Int J Cardiol*. 2011;151(2):232-234. doi:10.1016/j.ijcard.2011.06.044.
- 31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: RECEDE-CHF Trial Design

peer review only

e.g. Time	Interval	Urine		Blood	
0730	- 30				Arrives fasted. 2 x cannula sited
0745	- 15				15mls/kg oral water load over 15 minutes
0800	0				
0830	+ 30	Void urine. Water intake equal to urine volume.			
0900	+ 60	Void urine. Water intake equal to urine volume			
0930	+ 90	Void urine. Water intake equal to urine volume.			
0945	+ 105			Bloods (serum B1) for U&Es & osmolality	
1000	+ 120	Void urine. Water intake equal to urine volume. Collect urine (urine B1) for volume, sodium, creatinine & osmolality.	B1 (90-120 mins)		
1015	+ 135			Bloods (serum B2) for U&Es & osmolality	
1030	+ 150	Void urine. Water intake equal to urine volume. Collect urine (urine B2) for volume, sodium, creatinine & osmolality	B2 (120-150 mins)		IMP administered: Oral tablet (empagliflozin 20mg or placebo)
1045	+ 165		D1 (150-180 mins)	Bloods (serum D1) for U&Es & osmolality	
1100	+ 180	Void urine. Water intake equal to urine volume. Collect urine for volume, sodium, creatinine & osmolality			
1115	+ 195		D2 (180-210 mins)	Bloods (serum D2) for U&Es & osmolality	
1130	+ 210	Void urine. Water intake equal to urine volume. Collect urine for volume, sodium, creatinine & osmolality			IV furosemide administered: half participant's screening dose
1145	+ 225		F1 (210 - 240 mins)	Bloods (serum F1) for U&Es & osmolality	
1200	+ 240	Void urine. Water intake equal to urine volume. Collect urine for volume, sodium, creatinine & osmolality			
1215	+ 255		F2 (240-270 mins)	Bloods (serum F2) for U&Es & osmolality	
1230	+ 270	Collect urine for volume, sodium, creatinine & osmolality.			END OF STUDY PERIOD

Figure 2: Protocol for Renal Physiology Test Days



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 2 ___
	2b	All items from the World Health Organization Trial Registration Data Set	_____
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 21 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 21 ___
	5b	Name and contact information for the trial sponsor	___ 1 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 21 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____

1
2
3 **Introduction**
4

5 Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	___ 4-6 ___
	6b	Explanation for choice of comparators	___ 4-5 ___
10 Objectives	7	Specific objectives or hypotheses	___ 13 ___
12 Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___ 6-7 ___

15
16 **Methods: Participants, interventions, and outcomes**
17

18 Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	___ 2 ___
21 Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	___ 11-12 ___
24 Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	___ 2, 13-14 ___
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	___ 14 ___
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	___ 8 ___
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___ 12 ___
35 Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	___ 2, 13 ___

Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6-7, 8-9
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	14
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	14

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	12
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	11-13
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	12
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	12

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	15
-------------------------	-----	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

1			
2			
3		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols _____
4			
5			
6	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol _____ 15 _____
7			
8			
9			
10	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol _____ 15 _____
11			
12			
13		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) _____
14			
15		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) _____
16			
17			
18			
19	Methods: Monitoring		
20			
21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed _____ 16 _____
22			
23			
24			
25			
26		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial _____
27			
28			
29	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct _____ 16-17 _____
30			
31			
32	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor _____ 16 _____
33			
34			
35			
36	Ethics and dissemination		
37			
38	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval _____ 17 _____
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

1				
2				
3	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,	_____17_____
4	amendments		analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
5			regulators)	
6				
7	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	_____10_____
8			how (see Item 32)	
9				
10		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	_____
11			studies, if applicable	
12				
13	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	_____17_____
14			in order to protect confidentiality before, during, and after the trial	
15				
16	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____21_____
17	interests			
18				
19	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	_____18_____
20			limit such access for investigators	
21				
22	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	_____
23	trial care		participation	
24				
25				
26	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	_____17_____
27			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
28			sharing arrangements), including any publication restrictions	
29				
30		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
31				
32		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
33				
34				
35	Appendices			
36				
37	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	___not included___
38	materials			
39				
40	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	_____
41	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
42				

1
2 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
3 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
4 ["Attribution-NonCommercial-NoDerivs 3.0 Unported"](#) license.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only